Chronic hepatitis C: Hepatic fibrosis evolution after ineffective specific treatment

Hepato-Gastroenterology

Volumn 55, Issue 82-83, 2008, Pages 657-662

  Widman, Azzo ^a,b   Mendes Corrêa, Maria Cássia Jacyntho ^a   Zanoto, Arnaldo ^a   Capacci, Maria De Lourdes ^a   De Mello, Evandro Sobroza ^a   Saad, Willian Abrão ^a   Barone, Antonio Alci ^a   Gama Rodrigues, Joaquim José ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Evolution of hepatitis C; Hepatic biopsy; Hepatic fibrosis; Hepatic necroinflammation; Hepatic steatosis; Hepatitis C

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; BIOMETRY; BODY MASS; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; TIME; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; BIOPSY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 44349115550     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Shehab M, Orrego M, Chundri R, Lok ASF: Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98(3):539-644.
2. Rodger AJ, Thomson JA, Thompson SA, Jolley D, Mijch AM, Lanigan A, Crofts N: Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: Results of a pilot study. J Gastroenterol and Hepatol 1999; 14:269-273.
3. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. The NEJ Med 1999; 340(16):1228-1233.
4. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U: Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32(1):91-96.
5. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowich JH, Ludwig J, Okuda K: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23(3):1334-1340.
6. Roudot-Thoraval F, Bastie A, Pawlotsky J-M, Dhumeaux D and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus: Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997; 26(2):485-490.
7. Mahmood S, Niiyama G, Kawanaka M, Nakata K, Sho M, Yusuhara Y, Ito T, Yamada G: Long term follow-up of a group of chronic hepatitis C patients treated with anti-inflammatory drugs following initial interferon therapy. Hep Research 2002; 24:231-219.
8. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB: Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36(5):S161-172.
9. Kirlagkitsis I, Portmannn B, Smith H, O'Grady J, Cramp ME: Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98(7):1588-1593.
10. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Liddle C, Kench JG, Crewe E, Farrell GC: Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am JGastroenterol 2004; 99(4):636-644.
11. Gramenzi A, Andreone P, Fiorino S, Cammá C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxi A, Gasbarrini G, Bernardo M: Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48:843-848.
12. Kumar D, Farrell GC, Fung C, George J: Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36(5):1266-1272.
13. Olaso V, Casillo FJ, Cordoba J, Molina JM, Lopez L, Siles MS, Jaen J, Martinez F, Calvo F, Garijo R, Gobernado M: Retreatment with interferon plus ribavirin in chronic hepatitis C patients with genotype 1 who had no response or relapse with a previous interferon treatment. Rev Esp Quimioter 2002; 15(3):247-256.
14. Poynard T: Do the interferons have action? The hepatologist's point of view. Rev Med Int 2002; 23:S517-521.
15. Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S: The Italian Hepanet Group: Long-term liver histologic improvement in patients with chronic hepatitis C and sustained response to interferon. Viral Hepat 2003; 10(2):126-133.
16. Enokimura N, Shirakai K, Kawakita T, Saitou Y, Inoue H, Okano H, Yamamoto N, Deguchi M, Sakai T, Ohmori S, Fujikawa K, Murata I, Niki Y, Nakano T: Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res 2003; 23:593-596.
17. Gayotto LCC e Comitê SBP/SBH: Visão histórica e consensu nacional sobre a classificação das hepatites crônicas. GED 2000; 19(3):137-140.
18. Hollander A, Glaumann H, Weiland O: Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. Scand J Gastorenterol 2004; 39(2):164-167.
19. Liang TJ, Rehermann B, Seef LB, Hoofnagle JH: Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
20. Protocolo Clínico e Diretrizes Terapeuticas - Hepatite viral C: Ministério da Saude (Secretaria de Assistência à Saude) Portaria: 863 de 12/11/2002.
21. Forman E, Stauber R, Denk D-M, Jessner W, Zollner G, Munda-Steidl P, Gange A, Ferenci P: Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastronterol 2004; 99(5):873-877.
22. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC: Progression of hepatic fibrosis in patients with hepatitis C: a prospective liver biopsy study. Gut 2004; 53(3):318-321.
23. Collier JD, Woodall T, Wight DGD, Shore S, Gimson AE, Alexander GJM: Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat 2005; 12(1):74-80.
24. Asselah T, Boyer N, Guimont MC, Cazals-Haten D, Tubach F, Nahon K, Daika H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P: Liver fibrosis is not associated to steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2004; 52(11):1638-1643.
25. Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA: Overweight and obesity, hepatic steatosis and progression of chronic hepatitis C: a retrospective study on large cohort of patients in the United States. J Hepatol 2004; 40(1):147-154.
26. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A Bozzola L, Smedile A, Negro F: Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53(3):406-412.
27. Wyatt J, Baker H, Prasad P, Gong YY, Millson C: Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 2004; 57(4):402-406.
28. Khokhar N, Mushtaq M, Mukhtar AS, Ilahi F: Steatosis and chronic hepatitis C virus infection. J Pak Med Assoc 2004; 54(3):110-112.
29. Castera L, Hezode C, Rudot-Thoraval F, Bastie A, Zafrani E-S, Pawlotsky J-M, Dhumeaux D: Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52:288-292.
30. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, Powell EE: Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39(5):1230-1238.
31. Feldstein A: Steatohepatitis and apoptosis: therapeutic implications. Am J Gastorenterol 2004; 99:1718-1719.
32. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CMP: Hepatocyte apoptosis, expression of death receptors, activation of NF-kB in the liver of nonalcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99:1708-1717.